Common Pediatric Diseases and Disorders
Asthma is the most common chronic disease of childhood, affecting 1 in 10 children globally. It represents a chronic inflammatory disorder of the airways characterized by reversible airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation. As the leading cause of school absenteeism and pediatric hospitalizations, comprehensive understanding and management are essential for ensuring children can breathe easily and live fully.
π― Understanding Childhood Asthma
Asthma involves complex interactions between genetic predisposition, environmental triggers, and immune system dysregulation:
π₯ Pathophysiology Core Concepts
- Chronic Airway Inflammation: Persistent inflammation even when asymptomatic
- Bronchial Hyperresponsiveness: Exaggerated response to triggers (allergens, viruses, exercise)
- Reversible Airflow Obstruction: Responsive to bronchodilators (distinguishes from COPD)
- Key Players: Eosinophils, mast cells, T-helper 2 (Th2) cells, IgE antibodies
- Airway Remodeling: Structural changes with chronic inflammation (basement membrane thickening, smooth muscle hypertrophy)
- Key Point: Early, consistent anti-inflammatory treatment can prevent irreversible remodeling
π Epidemiology & Risk Factors
- Prevalence: 10% of children worldwide; increasing in urban areas
- Genetic Predisposition: One parent: 25% risk; Both parents: 50% risk
- Age of Onset: Most develop symptoms before age 5; 80% by age 6
- Gender Distribution: Boys > Girls in childhood (2:1); equalizes in adolescence
- Environmental Factors: Tobacco smoke (strongest modifiable risk), air pollution, indoor allergens
- Protective Factors: Farm exposure, older siblings, daycare attendance (hygiene hypothesis)
π― Clinical Memory Aid: Asthma Pathophysiology "Triad"
- Inflammation: Chronic, even when asymptomatic (needs controller therapy)
- Hyperresponsiveness: Airways overreact to triggers (explains variability)
- Obstruction: Reversible with treatment (distinguishes from other lung diseases)
- Key Principle: "Treat the inflammation, not just the symptoms"
π Clinical Presentation & Diagnosis
Asthma diagnosis is clinical, based on symptom patterns, physical findings, and response to therapy. No single test is diagnostic:
β‘ Classic Symptoms (The "Asthma Triad")
- Wheezing: High-pitched whistling sound, usually expiratory May be absent in severe obstruction ("silent chest" is ominous)
- Cough: Often dry, worse at night/early morning, with exercise/laughing Cough-variant asthma may present with cough as only symptom
- Dyspnea: Shortness of breath, chest tightness, difficulty breathing Children may describe as "tummy breathing" or "belly breathing"
- Key Features: Symptoms are VARIABLE (come and go), REVERSIBLE (respond to bronchodilators), and TRIGGERED (by specific factors)
ποΈ Physical Examination Findings
- General: Tachypnea, use of accessory muscles, tripod positioning
- Chest: Prolonged expiratory phase, wheezing, decreased breath sounds
- Severe Signs: Cyanosis, inability to speak in full sentences, altered mental status
- Between Attacks: May be completely normal (does NOT rule out asthma)
- Associated Findings: Allergic shiners, nasal crease, atopic dermatitis (eczema)
- Key Point: Normal exam between exacerbations is COMMON in asthma
π Diagnostic Criteria (GINA Guidelines 2023)
- History of variable respiratory symptoms: Wheeze, cough, dyspnea, chest tightness Symptoms vary over time and in intensity
- Documented variable expiratory airflow limitation: Spirometry showing obstruction with bronchodilator response FEVβ increase β₯12% AND β₯200 mL after bronchodilator
- Exclusion of alternative diagnoses: Consider cystic fibrosis, bronchiolitis, foreign body, vocal cord dysfunction Particularly important in atypical presentations
- Clinical prediction tools: Asthma Predictive Index (API) for children <3 years with recurrent wheezing Major criteria: Parental asthma, eczema; Minor: Allergic rhinitis, wheezing without colds, eosinophilia
- Key Point: Diagnosis is CLINICAL; normal spirometry does NOT exclude asthma
β οΈ HIGH-YIELD DIAGNOSTIC PEARLS:
- "Cough at night = asthma until proven otherwise" Especially if worse with activity or laughing
- Normal spirometry between attacks is COMMON (doesn't rule out asthma)
- Exercise-induced symptoms are HIGHLY SUGGESTIVE of asthma (EIB = Exercise-Induced Bronchoconstriction)
- Response to bronchodilator trial can be diagnostic (improvement with albuterol supports diagnosis)
- Consider asthma in ANY child with recurrent respiratory symptoms regardless of wheeze presence
π§ͺ Diagnostic Testing & Classification
Objective testing supports clinical diagnosis and guides management. Asthma severity is classified based on symptom frequency and treatment required:
π Spirometry (Gold Standard)
- FEVβ (Forced Expiratory Volume in 1 second): Most important parameter Reduced in obstructive disease; normal >80% predicted
- FVC (Forced Vital Capacity): Total volume exhaled May be normal or reduced in asthma
- FEVβ/FVC Ratio: Percent of FVC exhaled in first second Normal: >0.85 in children; Reduced in obstruction
- Bronchodilator Response: Increase in FEVβ β₯12% AND β₯200 mL after SABA Confirms reversible obstruction
- Age Considerations: Reliable after age 5-6 years; challenging in younger children
π Peak Expiratory Flow (PEF)
- What it measures: Maximum speed of exhalation (L/min) Effort-dependent; requires good technique
- Clinical use: Monitoring, NOT diagnosis Daily variability >20% suggests poor control
- Personal best: Highest reading over 2-3 weeks when well Zone system: Green (>80%), Yellow (50-80%), Red (<50%)
- Limitations: Less sensitive than FEVβ; effort-dependent; age/height dependent
π¬ Additional Testing
- FeNO (Fractional exhaled Nitric Oxide): Marker of eosinophilic inflammation Elevated in allergic asthma; guides steroid responsiveness
- Bronchoprovocation: Methacholine or exercise challenge For equivocal cases; positive if FEVβ drops β₯20%
- Allergy testing: Skin prick tests or specific IgE Identifies triggers; NOT diagnostic of asthma
- Chest X-ray: Typically normal; rules out other diagnoses Consider if atypical presentation or poor response to therapy
| Severity | Symptoms | Night Symptoms | Lung Function | SABA Use |
|---|---|---|---|---|
| Intermittent | β€2 days/week | β€2 nights/month | FEVβ β₯80% | β€2 days/week |
| Mild Persistent | >2 days/week but not daily | 3-4 nights/month | FEVβ β₯80% | >2 days/week |
| Moderate Persistent | Daily symptoms | >1 night/week | FEVβ 60-80% | Daily |
| Severe Persistent | Throughout the day | Frequent (β₯7 nights/week) | FEVβ <60% | Several times/day |
π₯ HIGH-YIELD: Asthma Phenotypes in Children
- Allergic (Extrinsic): Most common (80%); onset in childhood; family history; IgE-mediated
- Non-allergic (Intrinsic): Later onset; triggered by infections, exercise, irritants
- Exercise-induced (EIB): Symptoms only with exercise; responds to pre-treatment
- Cough-variant: Chronic cough as only symptom; responds to asthma therapy
- Virus-induced: Young children; symptoms only with viral infections; may outgrow
- Severe therapy-resistant: Poor control despite optimal therapy; consider alternative diagnoses
π Pharmacologic Management
Asthma management follows a stepwise approach based on symptom control. The goal is to use the minimum effective therapy to achieve control:
π― GINA 2023 Stepwise Approach (Children β₯6 Years)
- Step 1 (Mild): As-needed low-dose ICS-formoterol for symptoms Preferred over SABA-only approach; reduces exacerbations
- Step 2 (Mild Persistent): Daily low-dose ICS Controller therapy; choose lowest effective dose
- Step 3 (Moderate): Low-dose ICS + LABA (maintenance) OR medium-dose ICS LABA should NEVER be used alone (black box warning)
- Step 4 (Moderate-Severe): Medium-dose ICS + LABA Consider add-on therapy (LTRA, theophylline) if not controlled
- Step 5 (Severe): High-dose ICS + LABA + add-on therapy OR refer for biologic therapy Biologics: Omalizumab (anti-IgE), Mepolizumab (anti-IL-5), Dupilumab (anti-IL-4/13)
- Key Principle: Assess control every 1-3 months; step up if uncontrolled, step down if well-controlled for 3 months
| Medication Class | Examples | Mechanism of Action | Clinical Use | Key Points |
|---|---|---|---|---|
| Inhaled Corticosteroids (ICS) | Budesonide, Fluticasone, Beclomethasone | Reduce airway inflammation, decrease hyperresponsiveness | First-line controller; all persistent asthma | Local side effects only (thrush, hoarseness); minimal systemic absorption |
| Short-Acting Beta Agonists (SABA) | Albuterol, Levalbuterol | Bronchodilation via Ξ²2-receptor activation | Rescue medication for acute symptoms | Overuse (>2x/week) indicates poor control; NOT for daily use |
| Long-Acting Beta Agonists (LABA) | Formoterol, Salmeterol | Long-acting bronchodilation (12+ hours) | Add-on to ICS for moderate-severe asthma | NEVER use alone (increased mortality); always combined with ICS |
| Leukotriene Receptor Antagonists (LTRA) | Montelukast | Block leukotriene-mediated inflammation/bronchoconstriction | Alternative to ICS for mild; add-on for moderate-severe | Oral (once daily); especially good for EIB, allergic rhinitis co-morbidity |
| Biologic Therapies | Omalizumab, Mepolizumab, Dupilumab | Target specific inflammatory pathways (IgE, IL-5, IL-4/13) | Severe uncontrolled allergic/eosinophilic asthma | Subcutaneous injections; expensive; specialist initiation |
β οΈ CRITICAL MEDICATION SAFETY POINTS:
- ICS are SAFE in children: Minimal growth effects (1 cm first year only); poorly controlled asthma affects growth MORE
- LABA NEVER alone: Black box warning for increased asthma deaths when used without ICS
- SABA overuse kills: Frequent SABA use masks poor control and increases mortality risk
- Spacers are MANDATORY: For ALL MDI use in children; improve delivery 2-3x, reduce side effects
- Check technique EVERY visit: 70-80% of patients use inhalers incorrectly
- Step down when controlled: After 3 months of good control, reduce to lowest effective dose
π¨ Acute Asthma Exacerbation Management
Prompt recognition and treatment of asthma exacerbations prevent progression to respiratory failure. Early intervention is key:
π Severity Assessment & Initial Management
- Mild: Speaks in sentences, PEF >70%, O2 sat >95% Treatment: SABA 2-4 puffs via spacer, repeat every 20 min x3 if needed
- Moderate: Speaks in phrases, PEF 40-69%, O2 sat 90-95% Treatment: SABA + ipratropium via nebulizer, oral corticosteroids
- Severe: Speaks in words, PEF <40%, O2 sat <90%, accessory muscle use Treatment: Continuous SABA, IV corticosteroids, consider magnesium sulfate
- Life-threatening: Silent chest, cyanosis, altered consciousness, exhaustion Treatment: ICU admission, consider intubation, IV medications
- Key Principle: Early systemic corticosteroids reduce hospitalization by 60%
π¨ RED FLAGS REQUIRING IMMEDIATE INTERVENTION:
- Silent chest: No wheeze due to minimal air movement (NOT improvement)
- Cyanosis: Blue lips/fingernails indicates severe hypoxemia
- Altered consciousness: Confusion, agitation, drowsiness indicates hypercapnia
- Exhaustion: Child too tired to breathe effectively
- Inability to speak: Can only say 1-2 words between breaths
- Oxygen saturation <90%: On room air despite bronchodilators
- ACTION: Immediate ICU consultation, prepare for intubation
π©Ί EXACERBATION MANAGEMENT MNEMONIC: "ABCDE"
- Assess severity (speech, breath sounds, O2 sat, PEF)
- Bronchodilators (SABA Β± ipratropium)
- Corticosteroids (oral/IV early)
- Disposition (home vs hospital vs ICU)
- Education & follow-up (prevent recurrence)
π Asthma Action Plans & Education
Written asthma action plans (AAPs) are essential for self-management and reduce emergency healthcare utilization by 40-60%:
| Zone | Clinical Status | Peak Flow | Actions | When to Seek Help |
|---|---|---|---|---|
| GREEN (Doing Well) |
No symptoms day/night Normal activity No SABA needed |
>80% personal best | Continue controller medication SABA before exercise if needed |
Routine follow-up (3-6 months) |
| YELLOW (Caution) |
Increased symptoms Night waking Activity limited |
50-80% personal best | Increase controller (per plan) SABA every 4 hours as needed Start oral steroids if prescribed |
Contact doctor within 24-48 hours |
| RED (Medical Alert) |
Severe distress Difficulty speaking Trouble walking |
<50% personal best | SABA immediately (can repeat) Oral steroids (if not improving) Seek emergency care |
GO TO ER or CALL 911 NOW Don't delay! |
π₯ HIGH-YIELD: Essential Education Components
- Inhaler technique: Demonstrate, have patient demonstrate back, check EVERY visit
- Spacer use: MANDATORY for MDIs; wash monthly (not weekly) with dish soap
- Medication roles: Controllers (daily) vs Relievers (as-needed); analogies help
- Trigger avoidance: Individualized based on allergy testing/environment
- Written action plan: Personalized, reviewed at every visit, family understands
- Follow-up: Every 1-3 months until controlled, then every 3-6 months
- School communication: Provide plan to school nurse/teachers
π₯ Special Populations & Considerations
Tailored approaches for specific patient groups optimize outcomes and address unique challenges:
πΆ Infants & Young Children (<5 years)
- Diagnostic challenge: Spirometry not reliable; clinical diagnosis
- Asthma Predictive Index (API): Identifies wheezing preschoolers likely to have persistent asthma Major criteria: Parental asthma, eczema; Minor: Allergic rhinitis, wheezing without colds, eosinophilia
- Treatment: Trial of low-dose ICS (4-8 weeks); continue if response If no response, reconsider diagnosis
- Delivery devices: MDI + spacer + mask for infants/toddlers; nebulizer alternative
- Key Point: Many wheezy infants have virus-induced symptoms that resolve by school age
π₯ Adolescents
- Highest mortality risk: Poor adherence, risk-taking, denial of symptoms
- Adherence barriers: Embarrassment, forgetfulness, perceived invincibility
- Management strategies: Involve in decision-making, once-daily dosing, address mental health
- Transition to adult care: Begin planning at age 14, transfer 18-21 years
- Substance use: Smoking/vaping directly worsens asthma; screen and counsel
- Key Point: Adolescents need developmentally appropriate education and trust-building
π Exercise-Induced Bronchoconstriction (EIB)
- Prevalence: 40-90% of asthmatics, 10% of general population
- Pathophysiology: Airway cooling/drying β mast cell degranulation
- Prevention: SABA 15-30 minutes pre-exercise; leukotriene modifiers for frequent need
- Non-pharmacologic: Warm-up (induces refractory period), face mask in cold weather
- Key Point: EIB should NOT limit sports participation; many elite athletes have asthma
β οΈ COMMON PITFALLS IN ASTHMA MANAGEMENT:
- Under-treating inflammation: Fear of steroids leads to inadequate controller use
- Over-relying on SABA: Frequent use indicates poor control, not "just bad asthma"
- Poor inhaler technique: Most common reason for "treatment failure"
- Missing comorbidities: Allergic rhinitis, GERD, sinusitis worsen asthma control
- Not providing written plan: Verbal instructions insufficient for chronic disease
- Ignoring environmental triggers: Tobacco smoke exposure must be addressed
- Failure to step down: Continuing high-dose therapy when controlled
π§ Key Clinical Pearls
Essential considerations for successful asthma management in children:
π― MUST-KNOW PEARLS FOR PRACTICE
- "Cough at night = asthma until proven otherwise." Especially if worse with activity or laughing.
- "Inhaler technique is everything." Check at every visitβ70-80% of patients use inhalers incorrectly.
- "Spacers are mandatory for MDIs in children." Improve delivery 2-3x, reduce side effects.
- "Using SABA more than twice per week = poor control." Step up controller therapy.
- "Oral corticosteroids early in exacerbations save lives." Reduce hospitalization by 60%.
- "Silent chest is ominous, not reassuring." Indicates severe obstruction with minimal air movement.
- "ICS growth effects are minimal." Poorly controlled asthma affects growth more than steroids.
- "Every child needs a written action plan." Reduces ED visits by 40-60%.
- "Adolescence is highest mortality risk." Address adherence, risk-taking, mental health.
- "Asthma is controllable." With proper management, children can live completely normal lives.
π©Ί MONITORING PARAMETERS FOR ASTHMA CONTROL
- Well-controlled: Symptoms β€2 days/week, night symptoms β€2 nights/month, SABA β€2 days/week, normal activity
- Not well-controlled: Symptoms >2 days/week, night symptoms 1-3 nights/week, SABA >2 days/week, some limitation
- Very poorly controlled: Symptoms throughout day, night symptoms β₯4 nights/week, SABA several times/day, extreme limitation
- Exacerbations: Any urgent care, ED visit, hospitalization, or course of oral steroids
- Lung function: FEVβ or PEF β₯80% predicted/personal best indicates good control
π§ Conclusion
Childhood asthma is a common but highly manageable chronic condition that, with proper treatment, should not limit a child's activities or quality of life. The cornerstone of management is early and consistent anti-inflammatory therapy with inhaled corticosteroids, complemented by bronchodilators for symptom relief and written action plans for self-management.
Successful asthma care requires partnership between healthcare providers, children, and their families. This includes regular monitoring, ongoing education, attention to inhaler technique, environmental control measures, and management of comorbidities. The stepwise approach to pharmacotherapy ensures children receive the minimum effective treatment to achieve and maintain control.
Special attention must be paid to vulnerable periods including early childhood (diagnostic challenges), adolescence (adherence issues), and acute exacerbations (prompt intervention). With comprehensive management, nearly all children with asthma can achieve excellent control, participate fully in all activities including sports, and avoid long-term complications from airway remodeling.
Asthma management continues to evolve with new medications, delivery devices, and understanding of disease phenotypes. However, the fundamental principles remain: treat inflammation, monitor control, educate patients and families, and aim for complete normalization of life activities.
Asthma management philosophy: We cannot cure asthma, but we can control it so completely that children forget they have it. Our goal is not just symptom-free days, but symptom-free lives filled with play, sports, learning, and all the normal activities of childhood. With proper management, every child with asthma should be able to breathe easily and live fully.